Biomerica, Inc. (BMRA)
$1.80-2.70%Close
SELLCRISIS · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $6M
- Beta
- 0.31
- P/E (TTM)
- -1.43
- Short % float
- 1.00%
- Days to cover
- 1.0
- SI change
- -25.6%
- 1W
- -5.76%
- 1M
- -21.74%
- vs SPY 1W
- -4.78%
- vs SPY 1M
- -23.60%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 33
- GARP
- 2
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-58.3%
REV YoY-
ROE-43.5%
EPS YoY-
ROA-55.9%
GROSS8
OP-120
NET-85
[VALUATION]
P/E TTM-1.43
P/E FWD-
SECTOR PE20.48
INDUSTRY PE22.31
P/B2.10
P/FCF-
EV/EBITDA-1.65
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E71.60
ALTMAN Z-
CURR RATIO1.62
ND/EBITDA-
BETA0.31
NET INCOME (TTM) < 0
Company news
FAQ
- What is LOPJLB’s current signal on BMRA?
- LOPJLB’s latest quantitative signal on Biomerica, Inc. (BMRA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is BMRA in?
- Biomerica, Inc. (BMRA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Biomerica, Inc. (BMRA) do?
- Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complication…